news roundup
CISCRP released the results of its survey conducted in April on what the public and patients perceptions about clinical research in regard to the pandemic. Overall, awareness of clinical trials remains low—as 58% had not heard of a COVID-19 clinical research study recently.
EMA is engaging early with researchers to ensure that a European infrastructure will be in place to effectively monitor COVID-19 vaccines in the real world, once authorized in the European Union.
LabCorp’s drug development business, Covance, announced it will adopt Medable’s modular software platform as its patient and site interface to allow patients to participate in decentralized clinical trials.
|
|
|
advertisement
COVID-19 Serology Assays: To Test or Not to Test
Tuesday, June 2, 2020 at 11am EDT
Learn more
|
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
|
|
|
|
|
|
|
|
advertisement
Bioforum, the Forum for EmergingBio's Outsourcing Decisions
As the biopharma industry traverses unchartered waters amid the COVID-19 crisis and doubles down on its efforts to bring new therapies to market faster, cheaper and without affecting quality, the success of strategic partnerships and functional service provider models will become more critical than ever before.
Read the article
|
|
Articles |
|
Re-planning recruitment during the COVID-19 pandemic is a challenge, but can be started now despite the complexity and uncertainties related to the pandemic. The authors suggest creating multiple scenarios, ranging from the best to worst case assumptions, to assess a reasonable window-of-time, when recruitment may re-start and end.
|
|
The Tufts Center for the Study of Drug Development and Biogen recently conducted a study to inform growing interest in improving diversity of clinical trial participation. The results of this research are presented in this article and provide key insights into increasing the community of minority investigators and study staff and presenting greater access to clinical trials among minority study volunteers.
|
Blog Posts
Designing and operating clinical trials for diagnosing sepsis can be a challenge, as septic blood cultures predict sepsis only 14% of the time, which makes it a very challenging baseline for generating strong predictive data to prove novel diagnostics’ efficacy. Dr. Rolland Carlson, CEO of Immunexpress, discusses how the company overcame the challenges of implementing sepsis clinical trials.
|
|
|
|
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
